Lorenzo Leggio, M.D., Ph.D., M.Sc.

Investigator

Joint NIAAA-NIDA Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology

NIAAA

Building 10, Room 1-5429
10 Center Drive
Bethesda, MD 20892

301-435-9398

lorenzo.leggio@nih.gov

Research Topics

Dr. Leggio's CPN laboratory conducts clinical and translational inpatient and outpatient studies to identify possible novel medications for addiction. His group uses a combination of state-of-the-art and novel bio behavioral and pharmacological procedures performed under well-controlled human laboratory conditions. Imaging brain techniques, such as fMRI and PET, are also employed. Dr. Leggio and his team are particularly interested in the role of the gut-liver-brain axis in alcohol-seeking behaviors. Specifically, the CPN laboratory is currently investigating the potential role of feeding-related pathways, such as ghrelin, leptin, oxytocin and GLP-1, as possible new neuropharmacological targets for the treatment of alcohol use disorder. We have recently expanded our research looking at the role of the gut microbiota in heavy drinkers with a special emphasis on the relationships between alcohol-related seeking behaviors and the microbiota-gut-brain axis. Future research includes work on the effects of bariatric surgery on alcohol-related seeking behaviors. Both preclinical and human approaches are under development to shed light on the possible role of these pathways in alcohol use disorder.

Biography

Dr. Lorenzo Leggio serves as the Chief of the Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, a joint NIAAA and NIDA laboratory. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome and ‘Agostino Gemelli’ hospital, where he also completed residency and received Board Certification in Internal Medicine. He also received a Masters in ‘Alcohol-related diseases and problems’ from the University of Florence. He was a visiting research associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, Dr. Leggio joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio’s clinical research has been primarily focused on the treatment of alcohol use disorder, with a special emphasis on the role of feeding-related as well as GABAergic pathways; and on the medical consequences of alcohol use disorder, with a special emphasis on alcoholic liver disease. As a Principal Investigator at Brown University, Dr. Leggio received extramural research funding from NIAAA and NIDA, as well as from the European Foundation for Alcohol Research, Brown University CAAS, ABMRF/The Foundation for Alcohol Research, and the Brain & Behavior Research Foundation (formerly NARSAD). In June 2012, Dr. Leggio joined the NIAAA and NIDA Intramural Research Programs (IRPs) as a joint Tenure-Track Clinical Investigator and Section Chief. Clinically, Dr. Leggio serves as an NIH Senior Attending Medical Staff. Dr. Leggio also serves as the Associate Director for Clinical Research for the NIDA IRP Medication Development Program. Additionally, he is a Professor (Adjunct) at the Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University. Dr. Leggio’s lab has pioneered clinical research on the role of neuroendocrine signaling in alcohol-seeking behaviors via human laboratory studies. He has authored or co-authored over 130 peer-reviewed manuscripts and has served as a regular reviewer for many journals, reviewer for NIH study sections and other U.S. and international funding agencies and member of an FDA Advisory Board. He currently serves on the editorial board of several addiction-related journals and is a member of the Advisory Council of the Peter G. Dodge Foundation. Dr. Leggio has served as Chair (Medical/Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee, is a member of the American College of Neuropsychopharmacology and is also Founder and Chair of the Psychoneuroendocrinology Scientific Interest Group within the NIH IRP. Among other awards, he received the 2008 European Society for Biomedical Research on Alcoholism (ESBRA) Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award and the 2016 RSA Early Career Investigator Award.

Selected Publications

  1. Aoun EG, Jimenez VA, Vendruscolo LF, Walter NAR, Barbier E, Ferrulli A, Haass-Koffler CL, Darakjian P, Lee MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, Leggio L. A relationship between the aldosterone-mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. Mol Psychiatry. 2017.

  2. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-22.

  3. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA. Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry. 2014;76(9):734-41.

  4. Lee MR, Scheidweiler KB, Diao XX, Akhlaghi F, Cummins A, Huestis MA, Leggio L, Averbeck BB. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Mol Psychiatry. 2017.

  5. Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, Jerlhag E, Engel JA, Hodgkinson CA, Egli M, Lopez MF, Becker HC, Goldman D, Heilig M, Ramchandani VA, Leggio L. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry. 2015;5:e583.


This page was last updated on July 30th, 2017